In cancer, ADCC plays a crucial role in targeting and eliminating tumor cells. Monoclonal antibodies (mAbs) are often used in cancer therapy to target specific tumor antigens present on the surface of cancer cells. These mAbs bind to the antigens, flagging the cancer cells for destruction. NK cells, macrophages, and other immune cells then recognize the bound antibodies and initiate the cytotoxic response, leading to the death of the cancer cells.
